Guanhao Biotech Co

Guanhao Biotech Co EBIT Margin

The EBIT Margin (Operating Margin) of Guanhao Biotech Co (300238.SZ) as of Oct 31, 2026 is 7.65 %. In the previous year, EBIT Margin (Operating Margin) was 7.48 % — a change of 2.21% (higher).

EBIT Margin

7.65 %

YoY

2.21%

Last updated:

EBIT Margin (Operating Margin) of Guanhao Biotech Co is 2025 7.65 % . EBIT Margin (Operating Margin) of Guanhao Biotech Co was 2024 7.48 % . It decreases by 2.21% higher compared to the previous year.

For Guanhao Biotech Co, the operating (EBIT) margin of 7.6% is down versus 18.2% a few years ago.

The Guanhao Biotech Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
13.92 CNY
Jan 1, 2019
-111.18 CNY
Jan 1, 2020
10.29 CNY
Jan 1, 2021
18.19 CNY
Jan 1, 2022
-76.12 CNY
Jan 1, 2023
8.41 CNY
Jan 1, 2024
7.48 CNY
Jan 1, 2025
7.65 CNY
The Guanhao Biotech Co EBIT Margin history
YEAREBIT MarginYoY
7.65 %+2.21%
7.48 %-11.03%
8.41 %-111.05%
-76.12 %-518.45%
18.19 %+76.78%
10.29 %-109.26%
-111.18 %-898.88%
13.92 %+20.50%
11.55 %-23.33%
15.06 %-44.76%
27.27 %+1.58%
26.84 %+11,678.75%
0.23 %+1.01%
0.23 %-25.55%
0.30 %-8.29%
0.33 %+98.94%
0.17 %+25.30%
0.13 %-4.84%
0.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guanhao Biotech Co Stock analysis

What does Guanhao Biotech Co do? Guanhao Biotech Co Ltd develops and sells regenerative medical materials and implant devices, including biological dura mater patches, chest general surgery department patching membranes (type P and type B), asepsis biological wound-surface protection membranes, type B dura matrix, and intraocular lenses. The company generates revenue through the sale of these products to healthcare providers and medical institutions. Its primary customers are hospitals and surgical departments requiring advanced regenerative solutions for wound care and ophthalmic procedures. The firm also offers related technological services as part of its product portfolio. The company focuses on regenerative medical applications, targeting segments such as neurosurgery, general surgery, and ophthalmology. Its product range addresses specific clinical needs, including dura mater repair, wound protection, and vision correction. By providing specialized medical materials, Guanhao Biotech serves healthcare facilities seeking innovative solutions for patient recovery and surgical outcomes. Guanhao Biotech's core business revolves around the production and distribution of high-value medical devices and materials. The firm's revenue streams are derived from direct sales of its regenerative medical products and associated technological services. Key segments include hospitals, surgical departments, and ophthalmic clinics that utilize its specialized membranes and lenses for patient care. Guanhao Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guanhao Biotech Co stock

EBIT Margin (Operating Margin) of Guanhao Biotech Co is 7.65 % in 2025.

EBIT Margin (Operating Margin) of Guanhao Biotech Co changed from 7.48 % to 7.65 %, representing a 2.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Guanhao Biotech Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Guanhao Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Guanhao Biotech Co

All Key Metrics — Guanhao Biotech Co